Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimental Alport syndrome.

Kidney international - 1 Jun 2017

Bae Eun Hui, Fang Fei, Williams Vanessa R, Konvalinka Ana, Zhou Xiaohua, Patel Vaibhav B, Song Xuewen, John Rohan, Oudit Gavin Y, Pei York, Scholey James W

Abstract excerpt

Angiotensin-converting enzyme 2 (ACE2) is a monocarboxypeptidase in the renin-angiotensin system that catalyzes the breakdown of angiotensin II to angiotensin 1-7. We have reported that ACE2 expression in the kidney is reduced in experimental Alport syndrome but the impact of this finding on disease progression has not been studied. Accordingly, we evaluated effects of murine recombinant ACE2 treatment in Col4a3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Albuminuria
Share to Angiotensin-Converting Enzyme 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Angiotensins

Share to Collagen Type I

Share to Collagen Type I, alpha 1 Chain

Share to Collagen Type IV

Share to Mice, 129 Strain

Share to Nephritis, Hereditary

Source

Identifiers

PMID: 28249676
DOI: 10.1016/j.kint.2016.12.022

Genes

ACE2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimental Alport syndrome.PMID 28249676Read ↗

An update on the pathomechanisms and future therapies of Alport syndrome.Semantic proximity Read ↗

Exploration of Gene Therapy for Alport SyndromeSemantic proximity Read ↗

Treatment of Alport syndrome: beyond animal models.Semantic proximity Read ↗

Tauroursodeoxycholic acid ameliorates renal injury induced by COL4A3 mutation.Semantic proximity Read ↗

Irbesartan ameliorates kidney injury and anemia in a Col4a5-mutant mouse model of Alport syndrome with CKD pathologySemantic proximity Read ↗

Anti-microRNA-21 Therapy on Top of ACE Inhibition Delays Renal Failure in Alport Syndrome Mouse ModelsSemantic proximity Read ↗

Rediscovering ACE: novel insights into the many roles of the angiotensin-converting enzyme.Semantic proximity Read ↗

Zinc-α2-Glycoprotein Exerts Antifibrotic Effects in Kidney and HeartSemantic proximity Read ↗

Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations.Semantic proximity Read ↗

Renalase attenuates hypertension, renal injury and cardiac remodelling in rats with subtotal nephrectomy.Semantic proximity Read ↗

Animal models of renal fibrosis.Semantic proximity Read ↗

Renal Protection by Genetic Deletion of the Atypical Chemokine Receptor ACKR2 in Diabetic OVE Mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.